Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Aug 04, 2021 12:13pm
153 Views
Post# 33648523

RE:Biogens approval creates controversy but also opportunities

RE:Biogens approval creates controversy but also opportunities Interesting spin RC, I guess what you're saying is that by openly corrupting the FDA (more) Biogen has made it easier for others to do the same.  I could hardly disagree with that but I doubt it helps PMN as our execs don't leave any cash on the table for regulators.

It's all good though, McConnell and Pelosi seem to have agreed on the terms for a one-party MAGA state to kick off officially with the 2022 mid terms, so that plus the new vaccine pricing means big pharma will be shovelling money out the back door just to make room for all the newly printed money pouring in the front door. Along with thousands of others, PMN's IP will be absorbed sooner than later so you're just going to have to die rich, or at least with biilions of greenbacks of declining value.  


  
<< Previous
Bullboard Posts
Next >>